open access

Vol 20, No 4 (2016)
Review paper
Published online: 2016-12-29
Get Citation

Antihypertensive treatment in critical limb ischaemia

Anders Gottsäter, Peter M. Nilsson
·
Arterial Hypertension 2016;20(4):195-197.

open access

Vol 20, No 4 (2016)
STATE-OF-THE ART REVIEW
Published online: 2016-12-29

Abstract

Peripheral artery disease (PAD) is defined as atherosclerotic arterial occlusive disease of the lower extremities, manifesting as intermittent claudication (IC, pain induced by walking) or critical limb ischaemia (CLI, rest pain or ulcerations). PAD guidelines recommend strict control of cardiovascular risk factors, and European guidelines on hypertension recommend a blood pressure (BP) target < 140/90 mm Hg also in PAD patients. As the pressure in the affected extremity might be of relevance for the prognosis concerning limb salvage in CLI, the traditional approach was to avoid beta-blockers and allow a slightly higher BP in CLI. Both theoretical considerations and observational data support aggressive BP lowering also in CLI; however, in the absence of randomized studies on BP lowering in this setting it cannot be definitely established that current recommendations on BP lowering apply also in CLI.

Abstract

Peripheral artery disease (PAD) is defined as atherosclerotic arterial occlusive disease of the lower extremities, manifesting as intermittent claudication (IC, pain induced by walking) or critical limb ischaemia (CLI, rest pain or ulcerations). PAD guidelines recommend strict control of cardiovascular risk factors, and European guidelines on hypertension recommend a blood pressure (BP) target < 140/90 mm Hg also in PAD patients. As the pressure in the affected extremity might be of relevance for the prognosis concerning limb salvage in CLI, the traditional approach was to avoid beta-blockers and allow a slightly higher BP in CLI. Both theoretical considerations and observational data support aggressive BP lowering also in CLI; however, in the absence of randomized studies on BP lowering in this setting it cannot be definitely established that current recommendations on BP lowering apply also in CLI.

Get Citation

Keywords

peripheral artery disease, critical limb ischaemia, blood pressure

About this article
Title

Antihypertensive treatment in critical limb ischaemia

Journal

Arterial Hypertension

Issue

Vol 20, No 4 (2016)

Article type

Review paper

Pages

195-197

Published online

2016-12-29

Page views

852

Article views/downloads

2347

DOI

10.5603/AH.2016.0020

Bibliographic record

Arterial Hypertension 2016;20(4):195-197.

Keywords

peripheral artery disease
critical limb ischaemia
blood pressure

Authors

Anders Gottsäter
Peter M. Nilsson

References (29)
  1. Norgren L, Hiatt WR, Dormandy JA, et al. TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007; 45 Suppl S: S5–67.
  2. Fowkes FG, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013; 382(9901): 1329–1340.
  3. Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res. 2015; 116(9): 1509–1526.
  4. Nehler MR, Duval S, Diao L, et al. Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population. J Vasc Surg. 2014; 60(3): 686–695.
  5. Aronow WS, Ahn C, Kronzon I, et al. Prevalence of coexistence of coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women > or = 62 years of age. Am J Cardiol. 1994; 74(1): 64–65.
  6. Ness J, Aronow W. Prevalence of Coexistence of Coronary Artery Disease, Ischemic Stroke, and Peripheral Arterial Disease in Older Persons, Mean Age 80 Years, in an Academic Hospital-Based Geriatrics Practice. Journal of the American Geriatrics Society. 2015; 47(10): 1255–1256.
  7. Hirsch AT, Haskal ZJ, Hertzer NR, et al. American Association for Vascular Surgery, Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, ACC/AHA Task Force on Practice Guidelines Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease, American Association of Cardiovascular and Pulmonary Rehabilitation, National Heart, Lung, and Blood Institute, Society for Vascular Nursing, TransAtlantic Inter-Society Consensus, Vascular Disease Foundation. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006; 113(11): e463–e654.
  8. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013; 34(28): 2159–2219.
  9. Lane DA, Lip GYH. Treatment of hypertension in peripheral arterial disease. Cochrane Database Syst Rev. 2013(12): CD003075.
  10. Lane D, Lip G. Treatment of hypertension in peripheral arterial disease. Cochrane Database of Systematic Reviews. 2009.
  11. Lane DA, Lip GYH. Treatment of hypertension in peripheral arterial disease. Cochrane Database Syst Rev. 2013(12): CD003075.
  12. Diehm C. Antihypertensive therapy in arterial occlusive disease. Vasa. 1991; 33(Suppl.): 71–74.
  13. Khin NY, Dijkstra ML, Huckson M, et al. Hypertensive extracorporeal limb perfusion for critical limb ischemia. J Vasc Surg. 2013; 58(5): 1244–1253.
  14. Zaki M, Elsherif M, Tawfick W, et al. The Role of Sequential Pneumatic Compression in Limb Salvage in Non-reconstructable Critical Limb Ischemia. Eur J Vasc Endovasc Surg. 2016; 51(4): 565–571.
  15. Fowkes FG. Epidemiology of atherosclerotic arterial disease in the lower limbs. Eur J Vasc Surg. 1988; 2(5): 283–291.
  16. Mautner G, Mautner S, Roberts W. Amounts of coronary arterial narrowing by atherosclerotic plaque at necropsy in patients with lower extremity amputation. The American Journal of Cardiology. 1992; 70(13): 1147–1151.
  17. Aronow WS, Ahn C, Kronzon I, et al. Prevalence of coexistence of coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women > or = 62 years of age. Am J Cardiol. 1994; 74(1): 64–65.
  18. Ness J, Aronow W. Prevalence of Coexistence of Coronary Artery Disease, Ischemic Stroke, and Peripheral Arterial Disease in Older Persons, Mean Age 80 Years, in an Academic Hospital-Based Geriatrics Practice. Journal of the American Geriatrics Society. 2015; 47(10): 1255–1256.
  19. Aronow WS, Ahn C, Kronzon I. Association of valvular aortic stenosis with symptomatic peripheral arterial disease in older persons. Am J Cardiol. 2001; 88(9): 1046–1047.
  20. Sigvant B, Lundin F, Wahlberg E. The Risk of Disease Progression in Peripheral Arterial Disease is Higher than Expected: A Meta-Analysis of Mortality and Disease Progression in Peripheral Arterial Disease. Eur J Vasc Endovasc Surg. 2016; 51(3): 395–403.
  21. Defining the outcome of critical ischaemia: a one year prospective study. Br J Surg. 1986; 73: 321.
  22. Long-term mortality and its predictors in patients with critical leg ischaemia. The I.C.A.I. Group (Gruppo di Studio dell'Ischemia Cronica Critica degli Arti Inferiori). The Study Group of Criticial Chronic Ischemia of the Lower Exremities. Eur J Vasc Endovasc Surg. 1997; 14(2): 91–95.
  23. Barani J, Nilsson JA, Mattiasson I, et al. Inflammatory mediators are associated with 1-year mortality in critical limb ischemia. J Vasc Surg. 2005; 42(1): 75–80.
  24. Zettervall SL, Buck DB, Darling JD, et al. Increased preoperative pulse pressure predicts procedural complications and mortality in patients who undergo tibial interventions for critical limb ischemia. J Vasc Surg. 2016; 63(3): 673–677.
  25. Im SI, Rha SW, Choi BG, et al. Impact of uncontrolled hypertension on 12-month clinical outcomes following below-the-knee arteries (BTK) interventions in patients with critical limb ischemia. Clin Hypertens. 2016; 29: 22–29.
  26. Conte MS, Bandyk DF, Clowes AW, et al. Risk factors, medical therapies and perioperative events in limb salvage surgery: observations from the PREVENT III multicenter trial. J Vasc Surg. 2005; 42(3): 456–64; discussion 464.
  27. Flu HC, Lardenoye JHP, Veen EJ, et al. Morbidity and mortality caused by cardiac adverse events after revascularization for critical limb ischemia. Ann Vasc Surg. 2009; 23(5): 583–597.
  28. Wahlberg E, Jörneskog G. Patients with diabetes and critical limb ischemia have a high peripheral vascular resistance. Ann Vasc Surg. 1997; 11(3): 224–229.
  29. Jörneskog G. Why critical limb ischemia criteria are not applicable to diabetic foot and what the consequences are. Scand J Surg. 2012; 101(2): 114–118.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl